Details of the Drug

General Information of Drug (ID: DMZAYYD)

• Drug Name: HER2 antigen-specific cancer immunotherapeutic

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]

• Cross-matching ID: TTD ID: D04PMS

References

• [1] ClinicalTrials.gov (NCT01220128) Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer. U.S. National Institutes of Health.